Arturo Molina, MD, MS 🩺🔬🩸🧪🧬🦠😷

#Biotech #CMO #Heme/Onc #Stanford Adjunct Clinical Professor (Oncology) #1Dad #Stanford Medicine Alumni (SMAA) @UT-Austin🤘🏼Views my own. #BLM #FirstGen 🏳️‍🌈

[Protagonist Therapeutics @ProtagonistTx]

Another great EHA for Protagonist!

At this year's event, four rusfertide poster presentations highlighted Phase 3 VERIFY and long-term data from the REVIVE and THRIVE studies in polycythemia vera (PV).

As rusfertide continues to advance toward potential FDA approval in Q3, we're encouraged by the growing body of data supporting its potential to address an important unmet need
in PV.

Thank you to the investigators, patients and partners whose work continues to move these programs forward.

#EHA2026

[Dinesh V. Patel, PhD @ProtagonistCEO]

And the journey of great science in hematology to serve humankind continues. Well done team @ProtagonistTx

[Eleni Efstathiou @EfstathiouEleni]

Another win for precision medicine in prostate cancer ! Molecular / Genomic testing is a requirement for good clinical practice !
No excuses no delays and no patient left behind.
It takes a lot of such wins to stack and move the needle in our field and they are coming🙌🏻 @oncodaily @neerajaiims @scserendipity1 @OncoAlert #prostatecancer #precisionmedicine

[Stanford Department of Medicine @StanfordDeptMed]

Yesterday, #StanDOM joined @StanfordMed's Annual PRIDE Parade, open to all and celebrating love, community, and inclusivity. Proud to show up together in support of inclusion and belonging. 🌈

#StanfordPride #StanfordPride2026 #StanfordMed

[Protagonist Therapeutics @ProtagonistTx]

News: Four abstracts highlighting rusfertide in polycythemia vera (PV) will be presented at the 2026 European Hematology Association Congress (EHA2026 Congress), taking place June 11-14, 2026, in Stockholm, Sweden.

The presentations include analyses from the randomized, controlled Phase 3 VERIFY study, as well as long-term results from the Phase 2 REVIVE and THRIVE open-label extension studies.

Read more in our press release: https://t.co/ANnLzTV8tz

[Protagonist Therapeutics @ProtagonistTx]

Thank you to all who joined us at #TIDESUSA 2026 in Boston!

It was an honor to have our Executive Vice President and Chief Discovery Officer Ashok Bhandari, PhD, give a keynote presentation on Protagonist's story of revolutionizing peptide drug discovery through our unique multi-component technology platform. He also presented on what's next for our company as we advance a next-generation oral IL-17 antagonist peptide for inflammatory diseases.

Discover more about how we're addressing unmet needs with peptide technology: https://t.co/4nXHeT8OY3

[Protagonist Therapeutics @ProtagonistTx]

Today we are pleased to announce presentation of one-year Phase 3 Data for ICOTYDE™ (icotrokinra) in moderate-to-severe plaque psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

The data demonstrate lasting skin clearance and a favorable safety profile in a once-daily pill for moderate-to-severe plaque psoriasis, with results further supporting the differentiated profile of ICOTYDE, licensed to Janssen Biotech, Inc., a Johnson & Johnson company.

https://t.co/b42xlSZyIX

[Dinesh V. Patel, PhD @ProtagonistCEO]

Slow and steady does it. Humble beginnings from 2008 to now, but we are just not done yet. Repeat performance is the real charm. Cheers!

[Protagonist Therapeutics @ProtagonistTx]

What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.

#PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation

[Dinesh V. Patel, PhD @ProtagonistCEO]

Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence.

A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.

[Protagonist Therapeutics @ProtagonistTx]

Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis.

This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible.

Read more: https://t.co/0TNwYudXbD

[Protagonist Therapeutics @ProtagonistTx]

Happy International Women's Day! This year's theme, #GiveToGain, encourages a mindset of generosity and collaboration in support of women's advancement to create a better future for all.

We are proud of our Protagonist team for exemplifying this sentiment and celebrate their successes and contributions as we pursue our mission to improve patient lives. #IWD2026

[Dr. Amrita Krishnan @DoctorAKrishnan]

American cancer society gala: congratulations to Todd and Diane Kennedy who were honored as volunteers of the year. Thank you for leading the support group at city of hope and for your advocacy for MM research

[Protagonist Therapeutics @ProtagonistTx]

Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV).

Read more details in our latest press release: https://t.co/NTylXEIowQ

[Protagonist Therapeutics @ProtagonistTx]

Today is #RareDiseaseDay! 300 million people worldwide live with a rare disease and each one of their journeys is unique, as represented by our employees' zebra cookie creations.

From diagnostic odysseys to lack of approved treatments, those affected by rare diseases face numerous challenges that must be addressed with scientific innovation, ongoing advocacy, and increased awareness.

At Protagonist Therapeutics, patient stories and hope inspire what we do every day as we work towards bringing groundbreaking solutions and a brighter future for those living with polycythemia vera (PV).

[Protagonist Therapeutics @ProtagonistTx]

As communities gather worldwide to recognize #RareDiseaseDay on February 28th, we asked our Vice President of Clinical Ops, Antonieta Sosa, what moments in her work reinforce the importance of what we do for patients living with a rare disease like polycythemia vera (PV).

[Protagonist Therapeutics @ProtagonistTx]

Our President and @ProtagonistCEO, Dinesh V. Patel, PhD, will participate in multiple investment bank conferences taking place this March.

Access these webcasts in our latest press release: https://t.co/omCo3sw327

[Protagonist Therapeutics @ProtagonistTx]

That's a wrap for #JPM26! Thanks to all who connected with us this week.

On Tuesday, @ProtagonistCEO Dinesh V. Patel, PhD shared pipeline updates for icotrokinra and rusfertide, with NDAs submitted for both.

We’re looking ahead to more pipeline updates this year, including progress with PN-881 (oral IL-17, psoriasis) and PN-477 (multi-agonist obesity program).

A recording of our presentation is available here: https://t.co/amJL4gJ4Ez

[Protagonist Therapeutics @ProtagonistTx]

Happy holidays from Protagonist Therapeutics! Warmest wishes to you and yours this holiday season ❄️